chemotherapies, radiation therapies and immunotherapies.

CYT-6091, the first generation Aurimune nanomedicine and a first-in-class therapeutic, was shown to be safe and tumor-targeted in a Phase I Clinical Trial. CytImmune is raising funds to advance CYT-6091 through Clinical Trials.

All Aurimune™ products are built around a 27nm gold nanoparticle core. Gold is known to be safe, has a flexible chemistry including forming covalent bonds, and can be manufactured with scale and precision in GMP conditions. All Aurimune products carry Tumor Necrosis Factor Alpha (TNF). Additionally, CytImmune developed a patented gold pegylation technology to prevent Aurimune removal by the immune system. This stealth attribute allows Aurimune to remain in circulation long enough to concentrate inside solid tumors.

The Aurimune family of nanomedicines includes CYT-6091 and several second generation, multifunctional nanomedicines. Second generation nanomedicines use TNF to destroy tumor blood vessels, then deliver anti-cancer agents including chemotherapies and targeted biologics into the tumor. Preclinical data indicate this approach concentrates anti-cancer therapies inside solid tumors, which dramatically increases effectiveness while reducing drug-related side effects. Therapeutics delivered by second generation Aurimune products include:

• Common Small Molecule Chemotherapies: Paclitaxel, Doxorubicin, Gemcitabine • Targeted Therapies and Biologics: TNF, Interferon Gamma, Mono and Bi-valent SMAC Memetics